VERAXA Biotech AG (NASDAQ: VRXA) has shifted its focus to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and products following the completion of its business combination and the commencement of Nasdaq trading in June 2026, according to an update from Xlife Sciences AG (SIX: XLS). The Swiss incubator and accelerator, which remains a significant shareholder, said VERAXA secured a financing base to support its next development steps and remains an important part of its portfolio strategy.
Xlife Sciences also reported operational and scientific progress across its portfolio during the first half of 2026, including developments at x-kidney diagnostics, saniva diagnostics, Axenoll, FUSE-AI and inflamed pharma. The portfolio comprises 416 patents and patent applications, including 216 granted intellectual property rights, underscoring the depth of the company’s intellectual property position in the life sciences sector.
For the second half of 2026, Xlife Sciences said it will continue supporting VERAXA Biotech (NASDAQ: VRXA) in establishing industry partnerships while pursuing commercialization and further development across its portfolio. To view the full report, visit https://ibn.fm/LwLwP.
The news matters because VERAXA’s transition to a public company provides it with a financing base to accelerate its pipeline of antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. The company, founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), is advancing its ADCs and proprietary BiTAC formats into clinical development. Successful execution could bring new treatment options to patients with high unmet medical needs, while also validating Xlife Sciences’ incubator model.
For investors, the update offers a snapshot of Xlife Sciences’ broader portfolio, which spans technological platforms, biotechnology and therapies, medical technology, and artificial intelligence and digital health. The 416 patents and patent applications highlight the potential value embedded in these ventures. As Xlife Sciences continues to support its portfolio companies toward commercialization, the progress at VERAXA and other projects could serve as a catalyst for future value creation. More information about Xlife Sciences is available at www.xlifesciences.ch.
VERAXA’s latest news and updates are available in its newsroom at http://ibn.fm/VRXA. The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to more than 5,000 outlets, press release enhancement, social media distribution and tailored corporate communications solutions.
